SGX Submits IND for Cancer Candidate

December 3, 2007

The FDA has received SGX Pharmaceuticals’ investigational new drug (IND) application for SGX523, a treatment for patients with solid tumors

The company expects to begin Phase I trials with SGX523 in solid tumor cancer patients in early 2008.

Mike Grey, SGX’s president and CEO, said the application’s submission comes a quarter earlier than anticipated.